Statement: the primary trial did not record any skin infections in their patients.
Primary_evidence: Adverse Events 1:   Total: 2/4 (50.00%)   Atrial fibrillation 0/4 (0.00%)   Dehydration 1/4 (25.00%)   Fatigue (asthenia, lethargy, malaise) 1/4 (25.00%)   Pain - Back 1/4 (25.00%)   Urinary tract infection 0/4 (0.00%)   Dyspnea (shortness of breath) 0/4 (0.00%)   Pericardial effusion 0/4 (0.00%)   Thrombosis 0/4 (0.00%)   Skin infection 0/4 (0.00%)   Rash: hand-foot skin reaction 0/4 (0.00%) Adverse Events 2:   Total: 0/3 (0.00%)   Atrial fibrillation 0/3 (0.00%)   Dehydration 0/3 (0.00%)   Fatigue (asthenia, lethargy, malaise) 0/3 (0.00%)   Pain - Back 0/3 (0.00%)   Urinary tract infection 0/3 (0.00%)   Dyspnea (shortness of breath) 0/3 (0.00%)   Pericardial effusion 0/3 (0.00%)   Thrombosis 0/3 (0.00%)   Skin infection 0/3 (0.00%)   Rash: hand-foot skin reaction 0/3 (0.00%)